Q-omics provides the consensus-scored TMEM18-DT profile across patient tissues and cancer cell-line models. TMEM18-DT expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TMEM18-DT is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TMEM18-DT RNA expression shows 16,467 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KICH, and UVM as cancer lineages where TMEM18-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM18-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM18-DT survival associations across molecular data types. TMEM18-DT RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM18-DT RNA expression–survival associations across cancer types. High TMEM18-DT expression shows unfavorable associations in UVM, LGG, LIHC and KIRP, but favorable associations in UCS and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for TMEM18-DT RNA expression.
This table summarizes TMEM18-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM18-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM18-DT shows lower tumor expression in KICH, KIRP and UCEC and higher tumor expression in BLCA, CHOL and LUSC. The KICH box plot shows higher TMEM18-DT RNA expression in normal versus tumor tissue (log2 FC = −0.204, t-test p < 0.001).
This table shows molecular features associated with TMEM18-DT in patient tissues and cancer cell lines. In patient samples, TMEM18-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
